Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Pyxis Oncology (PYXS) over the last 5 years, with Dec 2024 value amounting to $12.9 million.

  • Pyxis Oncology's Share-based Compensation rose 3.09% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year change of. This contributed to the annual value of $12.9 million for FY2024, which is 23.61% down from last year.
  • As of FY2024, Pyxis Oncology's Share-based Compensation stood at $12.9 million, which was down 23.61% from $16.9 million recorded in FY2023.
  • Pyxis Oncology's 5-year Share-based Compensation high stood at $16.9 million for FY2023, and its period low was $44,000 during FY2020.
  • For the 3-year period, Pyxis Oncology's Share-based Compensation averaged around $15.2 million, with its median value being $15.8 million (2022).
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 14,538.64% in 2021, then fell by 23.61% in 2024.
  • Pyxis Oncology's Share-based Compensation (Yearly) stood at $44,000 in 2020, then spiked by 14,538.64% to $6.4 million in 2021, then skyrocketed by 144.74% to $15.8 million in 2022, then rose by 7.50% to $16.9 million in 2023, then fell by 23.61% to $12.9 million in 2024.